Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06393335 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 36 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 |
| May 1, 2024 |
| clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04173988 | Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 6 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06277011 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04803123 | Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL | terminated | Early Phase 1 | 3 | Dorothy Sipkins, MD, PhDOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | terminated | Early Phase 1 | 46 | AmgenINDUSTRY | 3 | Sep 1, 2023 | clinicaltrials |
| NCT04923919 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia | unknown | Early Phase 1 | 100 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04484532 | Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers | completed | Early Phase 1 | 130 | Roswell Park Cancer InstituteOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05744440 | Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04518345 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | completed | Early Phase 1 | 3 | Uma BorateOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02046694 | A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL | completed | Early Phase 1 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03825718 | A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | completed | Early Phase 1 | 29 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT01843634 | Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 10 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04227015 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | recruiting | Early Phase 1 | 72 | He HuangOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04626726 | Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT04532203 | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies | recruiting | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04532281 | A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma(SIR-MO-1101) | terminated | Early Phase 1 | 3 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | unknown | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04209712 | Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | unknown | Early Phase 1 | 6 | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaINDUSTRY | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04129099 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04321161 | Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | completed | Early Phase 1 | 10 | University of FreiburgOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04226989 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | unknown | Early Phase 1 | 72 | He HuangOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04264039 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | withdrawn | Early Phase 1 | 0 | Michael BoyiadzisOTHER | 1 | Apr 19, 2019 | clinicaltrials |
| NCT03825731 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 20 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01331590 | Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia | completed | Early Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01557686 | Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study(PACE-AL) | completed | Early Phase 1 | 20 | Universitetshospitalernes Center for SygeplejeOTHER | 1 | Mar 19, 2012 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2024source: clinicaltrials